Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Gradalis, Inc.
Modality
Cell therapy
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03073525CT.gov A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers | — | Completed | — | — | — |
NCT02725489CT.gov Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers | — | Completed | — | — | — |
NCT02346747CT.gov A Trial of Vigil for Participants With Ovarian Cancer | — | Active Not Recruiting | — | — | — |
NCT01867086CT.gov Salvage Ovarian FANG™ Vaccine + Carboplatinum | — | Completed | — | — | — |
NCT01551745CT.gov Salvage Ovarian FANG™ Vaccine + Bevacizumab | — | Completed | — | — | — |
NCT01309230CT.gov A Trial of FANG™ Vaccine for Participants With Ovarian Cancer | — | Completed | — | — | — |
NCT03842865CT.gov Expanded Access of Vigil in Solid Tumors | — | Temporarily Not Available | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ovarian Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Gemogenovatucel-T (this asset) | Gradalis, Inc. | P2 | CCC · 53 |
| Tisotumab Vedotin | Seagen Inc. | P2 | BB |
| TIL | Inge Marie Svane | P2 | BB |
| Olaparib | Shandong University | P4 | BB |
| Cis-Diamminedichloroplatinum Ii | Kalinski, Pawel, MD, PhD | P3 | BB |
| Adriamycin | Genmab | P3 | BB |
| Carboplatin | Fudan University | P4 | BB |
| OTL-38 | On Target Laboratories, LLC | P4 | BB |
| Irinotecan | ARCAGY/ GINECO GROUP | P4 | BB |
+42 more in the Ovarian Cancer cohort
Other indications for Gemogenovatucel-T
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Uterine Cancer | — | P2 | B · 57 |
| Ewing Sarcoma | — | P3 | B · 57 |
| Non-Small Cell Lung Carcinoma | — | P2 | B · 56 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Gemogenovatucel-T in Ovarian Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/gemogenovatucel-t-ovarian-cancer-27801
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →